Previous studies exploring associations between statin use and risk of multiple myeloma (MM) showed inconsistent results. We searched for articles published in English in databases (PubMed, Web of Science, EMBASE, Medline, and Google Scholar) before October 2019. The multivariate odds ratio (OR)/relative risk (RR) and 95% confidence intervals (CI) were computed to explore associations between statin use and risk of MM. The study indicated that statin users showed significantly lower risks of MM with a random effects model (OR/RR = 0.77, 95% CI 0.63 to 0.95, I2 = 63.1%, p for Q test = 0.001). Subgroup analyses showed that statin users showed significantly lower risks of MM in Caucasian populations with a fixed effects model (OR/RR = 0.72, 95% CI 0.59 to 0.88, I2 = 43.5%, p for Q test = 0.060), whereas no significant association was shown between statin use and risks of MM in Asian populations with a random effects model. Additionally, Subgroup analyses showed that statin users showed significantly lower risks of MM in cohort studies with a fixed effects model (RR = 0.83, 95% CI 0.74 to 0.93, I2 = 0.0%, p for Q test = 0.429), whereas no significant association was shown between statin use and risks of MM in case-control studies with a random effects model. In conclusion, the present study indicated that statin use might be a protective factor for MM incidence. However, the relationship between statin use and MM risk requires repeated and large prospective studies to be verified.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Rollig C, Knop S, Bornhauser M (2015) Multiple myeloma. Lancet (London, England) 385(9983):2197–2208. https://doi.org/10.1016/s0140-6736(14)60493-1
Rajkumar SV (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(7):719–734. https://doi.org/10.1002/ajh.24402
Kehrer M, Koob S, Strauss A, Wirtz DC, Schmolders J (2017) Multiple myeloma - current status in diagnostic testing and therapy. Z Orthop Unfallchirurgie 155(5):575–586. https://doi.org/10.1055/s-0043-110224
Kazandjian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 43(6):676–681. https://doi.org/10.1053/j.seminoncol.2016.11.004
Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, Patel AV, Adami HO, Weiderpass E, Giles GG, Singh PN, Alavanja M, Beane Freeman LE, Bernstein L, Buring JE, Colditz GA, Fraser GE, Gapstur SM, Gaziano JM, Giovannucci E, Hofmann JN, Linet MS, Neta G, Park Y, Peters U, Rosenberg PS, Schairer C, Sesso HD, Stampfer MJ, Visvanathan K, White E, Wolk A, Zeleniuch-Jacquotte A, de Gonzalez AB, Purdue MP (2014) Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol 166(5):667–676. https://doi.org/10.1111/bjh.12935
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52–iv61. https://doi.org/10.1093/annonc/mdx096
Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D (2008) Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52(22):1769–1781. https://doi.org/10.1016/j.jacc.2008.08.039
Osmak M (2012) Statins and cancer: current and future prospects. Cancer Lett 324(1):1–12. https://doi.org/10.1016/j.canlet.2012.04.011
Vallianou NG, Kostantinou A, Kougias M, Kazazis C (2014) Statins and cancer. Anti Cancer Agents Med Chem 14(5):706–712
Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ (2017) The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol 14(2):107–119
Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP (2014) Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 15(10):e461–e468. https://doi.org/10.1016/s1470-2045(14)70119-6
Huang BZ, Chang JI, Li E, Xiang AH, Wu BU (2017) Influence of statins and cholesterol on mortality among patients with pancreatic cancer. J Natl Cancer Inst 109(5):djw275
Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY (2011) Statins are associated with a reduced risk of gastric cancer: a population-based case-control study. Am J Gastroenterol 106(12):2098–2103. https://doi.org/10.1038/ajg.2011.277
Fortuny J, de Sanjose S, Becker N, Maynadie M, Cocco PL, Staines A, Foretova L, Vornanen M, Brennan P, Nieters A, Alvaro T, Boffetta P (2006) Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15(5):921–925. https://doi.org/10.1158/1055-9965.epi-05-0866
Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17(1):27–36. https://doi.org/10.1002/pds.1507
Pradelli D, Soranna D, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G (2015) Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. Cancer Med 4(5):770–780. https://doi.org/10.1002/cam4.411
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clin Res Ed) 339:b2535. https://doi.org/10.1136/bmj.b2535
Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Ulcickas Yood M, Engel LS, Taylor A, Fortuny J, Habel LA, Johnson CC (2017) Statin use and risk of multiple myeloma: an analysis from the cancer research network. Int J Cancer 141(3):480–487. https://doi.org/10.1002/ijc.30745
Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71(5):1763–1771. https://doi.org/10.1158/0008-5472.can-10-2953
Iwata H, Matsuo K, Hara S, Takeuchi K, Aoyama T, Murashige N, Kanda Y, Mori S, Suzuki R, Tachibana S, Yamane M, Odawara M, Mutou Y, Kami M (2006) Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 97(2):133–138. https://doi.org/10.1111/j.1349-7006.2006.00153.x
Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B (2016) Risk of multiple myeloma in a case-spouse study. Leuk Lymphoma 57(6):1450–1459. https://doi.org/10.3109/10428194.2015.1094693
Chiu BCH, Chen JH, Yen YC, Calip GS, Chien CR, Ahsan H, Shih YCT, Cheng KF (2015) Long term statin use and risk of multiple myeloma among 15.5 million Taiwanese adults: a retrospective cohort study. Blood 126(23):4198
Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D (2006) Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15(12):2342–2347. https://doi.org/10.1158/1055-9965.epi-06-0097
Trojan PJ, Bohatch-Junior MS, Otuki MF, Souza-Fonseca-Guimaraes F, Svidnicki PV, Nogaroto V, Fernandes D, Krum EA, Favero GM (2016) Pravastatin induces cell cycle arrest and decreased production of VEGF and bFGF in multiple myeloma cell line. Braz J Biol 76(1):59–65. https://doi.org/10.1590/1519-6984.11914
Slawinska-Brych A, Zdzisinska B, Mizerska-Dudka M, Kandefer-Szerszen M (2013) Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition. Leuk Res 37(5):586–594. https://doi.org/10.1016/j.leukres.2013.01.022
Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ (1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58(23):5294–5297
Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G (2004) The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104(6):1825–1832. https://doi.org/10.1182/blood-2003-12-4218
Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB, Guan YY (2011) Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol 670(2–3):356–364. https://doi.org/10.1016/j.ejphar.2011.09.031
Dai Y, Khanna P, Chen S, Pei XY, Dent P, Grant S (2007) Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 109(10):4415–4423. https://doi.org/10.1182/blood-2006-09-047076
This study received no funding.
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Zhang, P., Liu, B. Statin use and the risk of multiple myeloma: a PRISMA-compliant meta-analysis. Ann Hematol 99, 1805–1812 (2020). https://doi.org/10.1007/s00277-020-04157-5
- Multiple myeloma